CH117071A - Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations. - Google Patents

Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations.

Info

Publication number
CH117071A
CH117071A CH117071DA CH117071A CH 117071 A CH117071 A CH 117071A CH 117071D A CH117071D A CH 117071DA CH 117071 A CH117071 A CH 117071A
Authority
CH
Switzerland
Prior art keywords
solution
alkaline earth
alkali
hydrate
earth metal
Prior art date
Application number
Other languages
French (fr)
Inventor
Fischer Dr Roger
Original Assignee
Fischer Dr Roger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fischer Dr Roger filed Critical Fischer Dr Roger
Publication of CH117071A publication Critical patent/CH117071A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A61K51/1289Devices or containers for impregnation, for emanation, e.g. bottles or jars for radioactive water for use in radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Description

  

  Solution colloïdale destinée à     servir    de     véhicule-support    à des substances  radioactives et en particulier à des émanations de     radium.       La présente invention a pour objet une  solution colloïdale destinée à servir de     véhi-          cule-support    à des substances radioactives  et tout particulièrement à des émanations  de radium.  



  On sait en effet que les corps radioactifs  ont un champ d'application toujours plus  étendu, parmi eux particulièrement les éma  nations-. radon, thoron et     actinon.     



  Or, celles-ci sont     assez    difficilement ma  niables parce que très peu solubles dans  les solvants ordinaires.  



  Ces corps ont des emplois très divers.  La médecine leur demande la plus forte  contribution, qu'il s'agisse soit de médica  ments radioactifs sous forme d'injections,  soit d'eaux radioactives médicinales (traite  ment des néoplasmes; méthode du docteur       Kotzareff).     



  En outre, on recherche activement le  rôle de ces émanations sur la culture des  plantes, sur les engrais tout spécialement.  Parmi les solvants de ces émanations ou de  ces corps radioactifs, on a utilisé les col  loïdes     organiques    et     minéraux;    cependant    leur emploi en médecine peut être très  dangereux et les autres applications des  corps radioactifs ne demandent pas d'emploi  de ces substances particulièrement chères.  De plus, le coefficient de solubilité de l'éma  nation dans ces corps est assez faible.  



  Ils ne sont pas d'une préparation facile.  La solution colloïdale selon l'invention  obvie à ces graves inconvénients et permet  d'éviter l'ennui de manipulations excessive  ment délicates.  



  Cette solution, en     effet,    supporte de  hautes doses d'émanations dans un volume  de liquide très restreint. A l'aide de cette  solution on peut préparer des produits dont  l'emploi en thérapeutique, par exemple,  lorsque cette solution est chargée d'émana  tions, est sans danger et dont l'application  dans les autres domaines est aisée.  



  Cette solution est obtenue à l'aide des  ingrédients suivants  De l'eau,- comme solvant, un sel halogéné  d'un métal alcalin ou alcalino-terreux, un  colloïde organique, un acide aminé et un      hydrate d'un métal alcalin ou     alcalino-          terreux.     



  Elle peut être préparée par exemple  comme suit:  On dissout le colloïde organique dans  une solution de sel     halogéné    de métal alca  lin ou alcalino-terreux dans l'eau distillée.  



  Le colloïde peut être dissous à des con  centrations différentes en rapport avec la  charge d'émanations ou de substances radio  actives     -plus    ou moins considérables que de  vra supporter la solution; plus la concen  tration en forces radioactives doit être éle  vée, plus la concentration du colloïde est  élevée.  



  La suspension colloïdale se fait en  chauffant le colloïde dans la solution saline,  en prenant garde que les concentrations sa  lines soient conservées. Cela s'obtient soit  en     chauffant    sous réfrigérant (moyen cou  rant) soit en     chauffant    à l'autoclave le  colloïde dans la solution.  



  La solution faite et refroidie est en gé  néral d'un PI, d'environ 6 à 6,5 soit légère  ment acide: elle est additionnée avec toutes  les précautions d'asepsie, pour en respecter  la stérilité, de sel d'acide aminé.  



  Le mélange est fortement acide. On  mesure son Ph. On ramène le liquide à  l'alcalinité par adjonction d'un hydrate de  métal alcalino-terreux jusqu'à ce que le mé  lange final ait un Ph de 7,4 à 8. La so  lution est alors prête à l'usage. Elle supporte  toutes les charges radioactives employées  couramment.  



  Comme sel halogéné on emploie de pré  férence le chlorure de sodium dans la pro  portion voulue pour former une solution       physiologique        (8,35        %o        NaCI).     



  Le colloïde organique peut être la géla  tine telle qu'on la trouve dans le commerce,  en feuilles blanches, à la concentration de  2     %o    à     2%.        Son        but        est        de        fixer        la        subs-          tance    radioactive.  



  L'acide aminé peut être le     bichloi-hydrate     de lysine en poudre sèche (acide     di-amino          caproïque)    à la concentration de 1 pour  mille de solution gélatinée.    L'hydrate alcalino-terreux peut être l'eau  de chaux saturée [Ca (OH)     2]    stérile, ajoutée  en quantité suffisante pour amener le Pli du  mélange de 7,4 à 8.



  Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations. The present invention relates to a colloidal solution intended to serve as a carrier vehicle for radioactive substances and more particularly for radium fumes.



  We know, in fact, that radioactive bodies have an ever-expanding field of application, among them particularly ema nations. radon, thoron and actinon.



  However, these are quite difficult to manage because they are very poorly soluble in ordinary solvents.



  These bodies have a wide variety of jobs. Medicine demands the greatest contribution from them, whether it be for radioactive drugs in the form of injections or for medicinal radioactive water (treatment of neoplasms; method of Dr Kotzareff).



  In addition, the role of these emanations on the cultivation of plants, especially on fertilizers, is being actively researched. Among the solvents of these emanations or of these radioactive bodies, organic and mineral necks have been used; however, their use in medicine can be very dangerous and other applications of radioactive bodies do not require the use of these particularly expensive substances. In addition, the solubility coefficient of the emanation in these bodies is quite low.



  They are not easy to prepare. The colloidal solution according to the invention obviates these serious drawbacks and makes it possible to avoid the boredom of excessively delicate handling.



  This solution, in fact, supports high doses of emanations in a very small volume of liquid. Using this solution, products can be prepared whose use in therapy, for example, when this solution is loaded with emanations, is harmless and whose application in other fields is easy.



  This solution is obtained using the following ingredients Water, - as solvent, a halogenated salt of an alkali metal or alkaline earth metal, an organic colloid, an amino acid and a hydrate of an alkali metal or alkaline - earthy.



  It can be prepared for example as follows: The organic colloid is dissolved in a solution of halogenated alkaline or alkaline earth metal salt in distilled water.



  The colloid can be dissolved at different concentrations in relation to the charge of emanations or radioactive substances - more or less considerable than actually supporting the solution; the higher the concentration of radioactive forces, the higher the concentration of the colloid.



  The colloidal suspension is made by heating the colloid in the saline solution, taking care that the sa lines concentrations are maintained. This is obtained either by heating under refrigerant (medium current) or by autoclaving the colloid in the solution.



  The solution made and cooled generally has a PI, of about 6 to 6.5, or slightly acidic: it is added with all the precautions of asepsis, to respect its sterility, of amino acid salt. .



  The mixture is strongly acidic. Its Ph is measured. The liquid is brought back to alkalinity by adding an alkaline earth metal hydrate until the final mixture has a Ph of 7.4 to 8. The solution is then ready for use. use. It supports all commonly used radioactive charges.



  As the halogenated salt, sodium chloride is preferably used in the desired proportion to form a physiological solution (8.35% o NaCl).



  The organic colloid can be gelatin as found in commerce, in white sheets, at a concentration of 2% to 2%. Its purpose is to fix the radioactive substance.



  The amino acid may be dry powdered lysine bichloihydrate (di-amino caproic acid) at a concentration of 1 per thousand gelatin solution. The alkaline earth hydrate can be sterile [Ca (OH) 2] saturated lime water, added in sufficient quantity to bring the Pli of the mixture from 7.4 to 8.

 

Claims (1)

REVENDICATION I: Solution colloïdale destinée à servir de véhicule-support à des substances radioac tives et en particulier aux émanations de radium, solution caractérisée par le fait qu'elle est formée à l'aide d'eau comme solvant, d'un sel halogéné, d'un métal alcalin ou alcalino-terreux, d'un colloïde organique, d'un acide aminé et d'un hydrate de métal alcalin ou alcalino-terreux. SOUS-REVENDICATIONS 1 Solution selon la revendication I, dans la quelle le sel halogéné est du chlorure de sodium en solution physiologique. CLAIM I: Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations, solution characterized by the fact that it is formed using water as solvent, a halogenated salt , an alkali or alkaline earth metal, an organic colloid, an amino acid and an alkali or alkaline earth metal hydrate. SUB-CLAIMS 1 Solution according to claim I, in which the halogenated salt is sodium chloride in physiological solution. 2 Solution selon la revendication I, dans la quelle le colloïde organique est de la gé- latine, à la concentration de 2 %o à 2%. 3 Solution selon la revendication I, dans laquelle l'acide aminé est le bichlorhydrate de lysine (acide di-amino caproïque) à la concentration de 1 pour 1000 de solution gélatinée. 4 Solution selon la revendication I, dans laquelle l'hydrate est de la chaux Ca(OH)E, ajoutée en quantité suffisante pour amener le Ph du mélange de 7,4 à 8. 2. Solution according to claim I, in which the organic colloid is gelatin, at a concentration of 2% to 2%. 3 The solution of claim I, wherein the amino acid is lysine dihydrochloride (di-amino caproic acid) at a concentration of 1 per 1000 of gelatin solution. 4 The solution of claim I, wherein the hydrate is lime Ca (OH) E, added in an amount sufficient to bring the Ph of the mixture from 7.4 to 8. REVENDICATION II: Procédé pour la préparation de la solu tion selon la revendication I, suivant lequel on mélange avec de l'eau, un sel halogéné d uir métal alcalin ou alcalino-terreux, un colloïde organique, un acide aminé et un hydrate d'un métal alcalin ou alcalino-terreux. CLAIM II: Process for the preparation of the solution according to claim I, according to which one mixes with water, a halogenated salt of an alkali metal or alkaline earth metal, an organic colloid, an amino acid and a hydrate of an alkali or alkaline earth metal. SOUS-REVENDICATIONS 5 Procédé selon la revendication II, dans lequel on emploie comme sel halogéné le chlorure de sodium dans la proportion voulue pour former une solution physio- logique (8,3â %o NaCl). (S Procédé selon la revendication<B>11,</B> dans lequel on emploie comme colloïde organique la gélatine en feuilles blanches à la con centration de 2 0%o à 2()/o. 7 Procédé selon la revendication II, SUB-CLAIMS A process according to claim II, wherein sodium chloride is employed as the halogenated salt in the proportion desired to form a physiological solution (8.3% NaCl). (S A method according to claim <B> 11, </B> in which white sheet gelatin at a concentration of 20% o to 2 () / o is employed as the organic colloid. 7 Method according to claim II, dans lequel on emploie comme acide aminé le bichlorhydrate de lysine (acide di-amino caproïque) à la concentration de 1 pour 1000 de solution gélatinée. 8 Procédé selon la revendication II, dans lequel on ajoute l'hydrate alcalin ou alea- lino-terreux en proportion voulue pour que le Ph de la solution soit compris entre 7,4 et 8. 9 Procédé selon la revendication II, dans lequel on emploie de la chaux Ca(OH)a comme hydrate d'un métal alcalin ou alcalino-terreux. in which lysine dihydrochloride (di-amino caproic acid) at a concentration of 1 per 1000 of gelatin solution is employed as amino acid. 8 A method according to claim II, in which the alkali or alkaline earth hydrate is added in the desired proportion so that the pH of the solution is between 7.4 and 8. 9 Method according to claim II, in which it is uses lime Ca (OH) a as a hydrate of an alkali or alkaline earth metal.
CH117071D 1925-09-07 1925-09-07 Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations. CH117071A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH117071T 1925-09-07

Publications (1)

Publication Number Publication Date
CH117071A true CH117071A (en) 1926-10-16

Family

ID=4376099

Family Applications (1)

Application Number Title Priority Date Filing Date
CH117071D CH117071A (en) 1925-09-07 1925-09-07 Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations.

Country Status (1)

Country Link
CH (1) CH117071A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2808011A (en) * 1952-08-21 1957-10-01 Miller Hofft Inc Furnace for burning semi-liquid fuels

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2808011A (en) * 1952-08-21 1957-10-01 Miller Hofft Inc Furnace for burning semi-liquid fuels

Similar Documents

Publication Publication Date Title
US6926913B2 (en) Composition containing molecular iodine
CH616080A5 (en)
EP0316993B1 (en) Pharmaceutical compositions containing a derivative of 3-hydroxy-butanoic acid chosen among oligomers of this acid and among esters of this acid or of these oligomers with 1,3-butane-diol
HUE028425T2 (en) Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate
JP5297815B2 (en) Pharmaceutical composition
CA2119270A1 (en) Sparfloxacine salts and solutions containing them
CH117071A (en) Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations.
DE3853493T2 (en) Superoxide dismutase derivatives, process for their preparation and their use as medicines.
CN107582737A (en) A kind of compound chlorohexidene oral-cavity disinfectant and preparation method thereof
CH636766A5 (en) SOLUTION FOR INFUSION FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY AND A METHOD OF PREPARATION THEREOF.
DE2136067C3 (en) 3-fluoro-D-alanine, 3-fluoro-D-alanine-2-d, their salts and medicinal products containing these compounds
DE60317303T2 (en) Hemoglobin conjugates
JP2004315470A (en) Pharmaceutical preparation containing sodium iodide
BE336476A (en)
FR2468366A1 (en) Acetazolamide or methazolamide anti:glaucoma compsn. - is buffered at pH 6-9, using an aminoacid, esp. l-lysine, for local administration e.g. as an eyewash
JP3000490B2 (en) Anti-tineamyces agent
JP2010265209A (en) Iodine liquid preparation
FR2581311A1 (en) Pharmaceutical compositions for the treatment of colites and colopathies, based on thyme oil and cade essential oil.
GB1569380A (en) Pharmaceutical compositions comprising substituted phenyl-amino-alcohol and process for preparing these compositions
JPS59122420A (en) Local ointment
SU1824123A1 (en) Method of anesthetic treatment of fish
AT129764B (en) Process for the preparation of new water-soluble compounds of 2-phenylquinoline-4-carboxylic acid and its derivatives.
DE2416142A1 (en) ANTIULCUS AGENT
JPH05252895A (en) Tonic of inclusion compound of garlic component
AT160493B (en) Process for the production of radioactive tissues.